Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dompe' Farmaceutici Spa has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 distinct examiners and 6 distinct art units, showing that the pending work is distributed broadly across examination assignments rather than concentrated around one examiner.
REDWOOD, CHRISTOPHER EVAN is the busiest examiner, with 1 pending matter. Because the busiest examiner handles only 1 matter, prosecution planning should be organized by individual application and art-unit context. The difference between the office-action count and art-unit count also indicates that at least one art unit contains more than one pending matter, although the available data does not identify which one.
This profile calls for coordinated docket monitoring across multiple examination channels. Counsel may benefit from consistent claim-position records and issue tracking, while tailoring arguments to the examiner assigned to each matter.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
| FORD, VANESSA L | 1 | 37.9% | +39.6% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 5d |
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | REDWOOD, CHRISTOPHER EVAN | — |
| 18763519 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | WANG, CHANG YU | — |
| 18284951 | COMBINATION THERAPY FOR COVID-19 VACCINATION | ALAM, DANYAL HASSAN | — |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 19d overdue |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 5d |
| 18279708 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DAHLIN, HEATHER RAQUEL | 15d |
| 18763519 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | WANG, CHANG YU | — |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1675 | 1 |
| 1672 | 1 |
| 1674 | 1 |
| 1658 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | REDWOOD, CHRISTOPHER EVAN | 1629 | §103§112DP | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18763519 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | WANG, CHANG YU | 1675 | §102§103§112Other | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18284951 | COMBINATION THERAPY FOR COVID-19 VACCINATION | ALAM, DANYAL HASSAN | 1672 | §103§112 | Final Rejection | — | Pending | Sep 29, 2023 |
| 18279708 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | DAHLIN, HEATHER RAQUEL | 1629 | §102§103DP | Final Rejection | 15d | Pending | Aug 31, 2023 |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | FORD, VANESSA L | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §101§102§103§112 | Non-Final OA | 5d | Pending | Mar 03, 2023 |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 19d overdue | Pending | Aug 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDompe' Farmaceutici Spa has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Christopher Evan Redwood has the most, with 1 of Dompe' Farmaceutici Spa's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
